What signal did the establishment of the "National Pharmaceutical Affairs Commission" send?

The establishment of the National Pharmaceutical Council has six main responsibilities
.
This means that the adjustment of the list of key monitored drugs may be in the third stage of review
.
Judging from the published list, the composition of experts adjusted to the medical insurance catalog is slightly different
.
With the establishment of national pharmaceutical associations, provincial and prefectural pharmaceutical associations will also be established one after another.
In the future, drugs will face more challenges, whether it is catalog access or hospital access and medication
.
Recently, the General Office of the National Health and Health Commission issued a notice on the establishment of the National Health and Health Commission's Pharmacy Management and Pharmacotherapeutics Committee, and announced the list of the committees
.
The six main responsibilities of the State Pharmaceutical Affairs Commission are different from those of the medical insurance catalog adjustment expert group.
The notice shows that the main duties of the State Pharmaceutical Affairs Commission are as follows: Research the development status of the pharmaceutical management of medical institutions in China, and put forward policy recommendations; around the establishment and improvement of drug selection in medical institutions Provide technical support for systems such as pharmacy, procurement, use, and evaluation; promote the implementation of clinical diagnosis and treatment guidelines related to drug therapy and guidelines for clinical application of drugs; promote the establishment and improvement of China's pharmacy service system, strengthen the construction of pharmacists, and standardize and develop pharmacy services; group drug injury incidents; undertake other tasks assigned by the National Health Commission
.
The committee office is located in the Medical Administration and Hospital Administration Bureau of the National Health and Health Commission and is responsible for daily work
.
The term of office of the members of the committee is 3 years from the date of this notice
.
Judging from the published list, the main committee members are experts in clinical medicine, pharmacy, pharmacy management and policy research from major hospitals
.
This is still different from the members of the expert group for the adjustment of the National Medical Insurance Catalogue
.
Judging from the "2021 National Medical Insurance Drug Catalog Adjustment Work Plan", although the third stage is also an expert review stage, the fourth stage involves the calculation of medical insurance funds and negotiating experts.
The composition of these experts is also different.
Experts in the field are mostly organized from the perspective of fund calculation: The review experts are divided into comprehensive groups and professional groups: Comprehensive group review experts: They are composed of upright >
.
Professional group review experts: recommended by relevant academic groups and industry (association) associations, mainly responsible for making comments and suggestions on the review opinions of the comprehensive drug group in this professional field, and for negotiating the main specifications of the drugs to be negotiated, reference drugs and limited payment scope, etc.
Make suggestions
.
Calculation experts: composed of experts in medical insurance management, pharmacoeconomics, etc.
recommended by local medical insurance departments and related units
.
It is divided into a fund calculation group and a pharmacoeconomics calculation group, which respectively put forward evaluation opinions on the negotiated drugs from the influence of medical insurance funds and the evaluation of pharmacoeconomics
.
Negotiation experts: composed of representatives of the medical insurance department and relevant experts, responsible for on-site negotiations with negotiating drug companies to speed up the adjustment of the list of key monitoring drugs "Notice on the Work Procedures for Adjustment of the Drug Catalog", which mentions that the State Pharmaceutical Affairs Administration and Therapeutics Committee (hereinafter referred to as the National Pharmaceutical Council) provides professional technical support for the scientific adjustment of the catalogue, and undertakes the aggregation, sorting and analysis of recommended materials in various places, etc.
work
.
The adjustment of the catalog includes four stages: start-up adjustment, local selection and recommendation, expert summary, and announcement of results.
The third stage: the National Health and Health Commission entrusts the National Pharmaceutical Council to conduct a formal review of the materials submitted by each region, and adopts the same procedure as the provincial level.
The same calculation method of the health and health administrative department is used to obtain the top 30 varieties
.
The establishment of the National Pharmaceutical Association and the release of the list of members may also mean that the adjustment of the catalog is being accelerated.

.
In the future, the fourth-level pharmaceutical committee will decide on drug market access and hospital use.
However, speaking of the National Pharmaceutical Affairs Commission, it must be traced back to the National Health Commission and other six departments jointly issued on February 26, 2020, "On Strengthening the Drug Administration in Medical Institutions".
The document "Opinions on the Administration of Matters for Promoting Rational Use of Drugs"
.
The opinion puts forward: "Strengthen the role of the pharmacy management and pharmacotherapy committees in medical institutions, and establish national, provincial, and prefecture-level pharmaceutical management and pharmacotherapy committees
.
" That is to say, in addition to the pharmaceutical affairs of each medical institution itself In addition to the meeting, there are also national, provincial, and municipal levels.
There are four levels of pharmaceutical committees.
With the continuous optimization and improvement of the relevant structures and functions of these four-level pharmaceutical committees, the management of pharmaceutical services will also be more unified.
and reinforcement
.
For pharmaceutical companies, this means that in the future, whether it is access to various catalogues, or hospital access and drug use, these new pharmacy committees at all levels will make the market access work of drugs more challenging.
It is also more complex and uncertain, and the work of the pharmaceutical company access department also needs to be reorganized.

.
Attachment: List of Pharmacy Management and Pharmacotherapeutics Committee of National Health and Health Commission (sorted by surname strokes) 1.
Consultant Ning Guang National Clinical Research Center for Metabolic Diseases Shang Hong National Medical Laboratory Clinical Medical Research Center Zhao Yupei Peking Union Medical College Hospital Zhong Nanshan National Respiratory Medical Center Gao Runlin National Cardiovascular Center Jiang Jiandong Chinese Academy of Medical Sciences Hejie National Cancer Center Zhang Shuyang Peking Union Medical College Hospital Third, Deputy Director Shi Luwen School of Pharmacy Peking University Li Weimin Sichuan University West China Hospital Zheng Junhua Shanghai Jiaotong University School of Medicine Renji Hospital Ni Xin, Beijing Children's Hospital Affiliated to Capital Medical University, Zhen Jiancun, Beijing Jishuitan Hospital, Yan Qing, National Health Commission Hospital Management Institute Fourth, member